Genetic mutations associated with sensitivity to neoadjuvant chemotherapy in metastatic colon cancer: A case report and review of literature

Table 3 Findings of chemotherapy-related single nucleotide polymorphisms related to a better response

Genes	Detected loci	SNP results	Evidence		Summary
			Drugs	Grades
DPYD	rs3918290	CC (wild-type)	5Fu-based	Level III	For patients with tumor, CC genotype may have a higher drug remission rate than CT genotype. However, there are also studies with inconsistent conclusions
	rs1801159	TT (wild-type)		Level III	For a patient with tumor, TT genotype may have a higher drug remission rate than CT or CC genotype
GSTP1	rs1695	AG (heterozygous mutants)	5Fu + XELOX	Level IIA	For a patient with tumor, AG genotype may have a higher drug remission rate than AA genotype, but comparing with GG genotype, AG genotype may reduce drug remission rate and relate to a poor OS
ERCC2	rs13181	TT (wild-type)	5Fu + Leucovorin + XELOX	Level III	For a patient with CRC, TT genotype may have a lower risk of recurrence and a longer PFS than GG genotype
	rs1052555	GG (wild-type)	Platinum compounds	Level III	For a patient with NSCLC, GG genotype may have a higher drug remission rate than AA or AG genotype
ABCB1	rs1045642	GG (homozygous mutants)		Level III	For a patient with CRC, GG genotype may have a higher drug remission rate than AA or AG genotype
VEGFA	rs25648	CC (wild-type)		Level III	For a patient with gastric cancer, CC genotype may have a higher drug remission rate than CT or TT genotype

CRC: Colorectal cancer; NSCLC: Non-small-cell lung cancer; OS: Overall survival; SNPs: Single nucleotide polymorphisms; XELOX: Oxaliplatin.